Trial reportClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2007
Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection.
Trial report in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 4 syntheses or guidelines pooled it, 133 citations in OpenAlex.
- Comparative efficacy and safety of biologic therapies in pediatric asthma: a comprehensive systematic review.Frontiers in medicine · 2026Pooled it
- European Guideline (EuroGuiDerm) on atopic eczema: Living update.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Guideline
- Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review.Drug safety · 2018Pooled it
- Asthma in adults.BMJ clinical evidence · 2011Pooled it
- [Biologics and infections: understand and recognize].Dermatologie (Heidelberg, Germany) · 2026Review
- Biologic Use in Type 2 versus Non-Type 2 Asthma: Similarities, Differences, and Challenges.Journal of inflammation research · 2026Review
- Liver-targeted allergen immunotherapy rapidly and safely induces antigen-specific tolerance to treat allergic airway disease in mice.Science translational medicine · 2025Article
- Case Report: Allergic Bronchopulmonary Aspergillosis and Tropical Pulmonary Eosinophilia Co-Occurrence Masquerading as Refractory Allergic Bronchopulmonary Aspergillosis.The American journal of tropical medicine and hygiene · 2024Article
- An Update on the Pathogenesis of Fascioliasis: What Do We Know?Research and reports in tropical medicine · 2024Review
- Diagnosis of Tuberculosis in a Case of Chronic Urticaria following Omalizumab Therapy.Antibiotics (Basel, Switzerland) · 2023Article
- Unanswered questions on the use of biologics in pediatric asthma.The World Allergy Organization journal · 2023Review
- Research Advances in Mast Cell Biology and Their Translation Into Novel Therapies for Anaphylaxis.The journal of allergy and clinical immunology. In practice · 2023Review
- Long-Term Safety of Omalizumab in Children with Asthma and/or Chronic Spontaneous Urticaria: A 4-Year Prospective Study in Real Life.Journal of personalized medicine · 2023Article
- Secondary immunodeficiencies and infectious considerations of biologic immunomodulatory therapies.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2023Review
- Development of Demodicosis after Omalizumab Injection.Annals of dermatology · 2023Article
- Parasitic Infections and Biological Therapies Targeting Type 2 Inflammation: A VigiBase Study.American journal of respiratory and critical care medicine · 2023Article
- Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration's adverse event reporting system (FAERS).Frontiers in pharmacology · 2023Article
- Risks and safety of biologics: A practical guide for allergists.The World Allergy Organization journal · 2023Review
- Therapeutical Targets in Allergic Inflammation.Biomedicines · 2022Review
- Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma.Journal of personalized medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough the role of immunoglobulin E (IgE) in immunity against helminth parasites is unclear, there is concern that therapeutic antibodies that neutralize IgE (anti-IgE) may be unsafe in subjects at risk of helminth infection.
objectiveWe conducted an exploratory study to investigate the safety of omalizumab (anti-IgE) in subjects with allergic asthma and/or perennial allergic rhinitis at high risk of intestinal helminth infection. The primary safety outcome was risk of infections with intestinal helminths during anti-IgE therapy.
methodsA randomized, double-blind, placebo-controlled trial was conducted in 137 subjects (12-30 years) at high risk of geohelminth infection. All subjects received pre-study anthelmintic treatment, followed by 52 weeks' treatment with omalizumab or placebo.
resultsOf the omalizumab subjects 50% (34/68) experienced at least one intestinal geohelminth infection compared with 41% (28/69) of placebo subjects [odds ratio (OR) 1.47, 95% confidence interval (CI) 0.74-2.95, one-sided P=0.14; OR (adjusted for study visit, baseline infection status, gender and age) 2.2 (0.94-5.15); one-sided P=0.035], providing some evidence for a potential increased incidence of geohelminth infection in subjects receiving omalizumab. Omalizumab therapy was well tolerated, and did not appear to be associated with increased morbidity attributable to intestinal helminths as assessed by clinical and laboratory adverse events, maximal helminth infection intensities and additional anthelmintic requirements. Time to first infection (OR 1.30, 95% CI 0.79-2.15, one-sided P=0.15) was similar between treatment groups. Infection severity and response to anthelmintics appeared to be unaffected by omalizumab therapy.
conclusionsIn this exploratory study of allergic subjects at high risk of helminth infections, omalizumab therapy appeared to be safe and well tolerated, but may be associated with a modest increase in the incidence of geohelminth infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.